Telomir Pharma grants director 50,000 stock options

Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, equal to the closing price that day, and vested immediately upon issuance. They are exercisable for common stock and expire on April 16, 2036, resulting in Del Giudice holding 50,000 options after the grant, awarded under the company’s 2023 Omnibus Incentive Plan. The transaction was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Del Giudice Matthew Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Options (right to buy) F1, F2	50,000	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Options (right to buy) — 50,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
2. F2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.

Key Figures

Options Granted: 50,000 options Exercise Price: $1.34 per share Post-Grant Option Holdings: 50,000 options +1 more

4 metrics

Options Granted 50,000 options Non-qualified stock options granted to director on April 16, 2026

Exercise Price $1.34 per share Exercise price equal to closing common stock price on April 16, 2026

Post-Grant Option Holdings 50,000 options Total options held by Matthew Paul Del Giudice after the transaction

Option Expiration Date 2036-04-16 Expiration date of the granted non-qualified stock options

Key Terms

Non-Qualified Stock Options, exercise price, 2023 Omnibus Incentive Plan, Rule 10b5-1

4 terms

Non-Qualified Stock Options financial

"security_title: "Non-Qualified Stock Options (right to buy)""

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"The exercise price of the stock options issued to the Reporting Person"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2023 Omnibus Incentive Plan financial

"pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan"

Rule 10b5-1 regulatory

"Rule 10b5-1 trading plans affect how insider transactions are pre-arranged"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Telomir Pharmaceuticals (TELO) disclose for Matthew Paul Del Giudice?

Telomir Pharmaceuticals disclosed that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options. The options were awarded on April 16, 2026, vesting immediately and giving him the right to purchase common stock at a fixed exercise price.

What is the exercise price of the Telomir (TELO) stock options granted to Matthew Paul Del Giudice?

The granted options carry an exercise price of $1.34 per share. This price equals the closing price of Telomir’s common stock on April 16, 2026, aligning the option strike with the market price on the grant date.

How many Telomir (TELO) options does Matthew Paul Del Giudice hold after this grant?

After the grant, Matthew Paul Del Giudice holds 50,000 stock options. These options were all acquired in this single award and represent his reported post-transaction derivative holdings in Telomir common stock options.

When do Matthew Paul Del Giudice’s Telomir (TELO) stock options expire?

The options granted to Matthew Paul Del Giudice expire on April 16, 2036. This gives him a ten-year window from the April 16, 2026 grant date to exercise the options and purchase Telomir common shares.

Did the Telomir (TELO) option grant to Matthew Paul Del Giudice vest immediately?

Yes, all of the granted options vested immediately upon issuance. According to the disclosure, the entire 50,000-option award was fully vested on April 16, 2026, with no additional time-based vesting conditions remaining.

Was the Telomir (TELO) option grant to Matthew Paul Del Giudice made under a Rule 10b5-1 trading plan?

No, the grant was not made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox associated with the reported transaction is marked as false, indicating it is not pursuant to an established trading plan.

Under which plan were the Telomir (TELO) options granted to Matthew Paul Del Giudice?

The options were granted under Telomir’s 2023 Omnibus Incentive Plan, as amended and restated. This plan governs the terms of the award, including the immediate vesting and the right to acquire common stock upon exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:30 PM Accepted by SEC EDGAR 07/27/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Del Giudice Matthew Paul

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

MIAMI FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Options (right to buy)	$1.34(1)	04/16/2026		A		50,000		(2)	04/16/2036	Common Stock	50,000	$0	50,000(2)	D

Explanation of Responses:

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.

2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.

	/s/ Matthew Del Giudice	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)